

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Union Medical Healthcare Limited

香港醫思醫療集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2138)

VOLUNTARY ANNOUNCEMENT LAUNCH OF RT-PCR COVID-19 TEST

This announcement is made by Union Medical Healthcare Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis. The Group has launched the sale of RT-PCR COVID-19 Test. The deep throat saliva RT-PCR lab test has been approved by the relevant European and American authorities, including California Department of Food and Agriculture (CFDA), Centers for Disease Control and Prevention (CDC) and Conformité Européene In Vitro Diagnostic Medical Device (CE-IVD).

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board of
Union Medical Healthcare Limited
Raymond Siu
Company Secretary

Hong Kong, 23 July 2020

As at the date of this announcement, the executive directors of the Company are Mr. Tang Chi Fai, Mr. Lee Gabriel, Mr. Lee Heung Wing and Mr. Wong Chi Cheung; the non-executive directors of the Company are Mr. Luk Kun Shing Ben and Dr. Steven Wang Dasong, and the independent non-executive directors of the Company are Mr. Ma Ching Nam, Mr. Look Andrew and Mr. Lam Chi Hang Josekin.

**For identification purpose only*